Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 156.25 | 92.36 | 98.00 | 130.25 | 0.7524 | 0.1269 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 156.25 | 92.36 | 132.00 | 130.25 | 1.0134 | 1.0546 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 156.25 | 92.36 | 454.00 | 130.25 | 3.4856 | 23.8075 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 156.25 | 92.36 | 106.00 | 130.25 | 0.8138 | 0.3201 |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 156.25 | 92.36 | 141.00 | 130.25 | 1.0825 | 1.3468 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 144.00 | 130.25 | 1.1056 | 1.4486 | |
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 156.25 | 92.36 | 132.00 | 130.25 | 1.0134 | 1.0546 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 225.00 | 130.25 | 1.7274 | 5.0225 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 156.25 | 92.36 | 73.00 | 130.25 | 0.5605 | -0.3778 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 156.25 | 92.36 | 143.00 | 130.25 | 1.0979 | 1.4145 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 127.00 | 130.25 | 0.9751 | 0.9006 | |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 156.25 | 92.36 | 156.00 | 130.25 | 1.1977 | 1.8776 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 156.25 | 92.36 | 40.00 | 130.25 | 0.3071 | -0.8150 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 156.25 | 92.36 | 81.00 | 130.25 | 0.6219 | -0.2326 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 156.25 | 92.36 | 62.00 | 130.25 | 0.4760 | -0.5524 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 168.00 | 130.25 | 1.2898 | 2.3414 | |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 125.00 | 130.25 | 0.9597 | 0.8408 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 156.25 | 92.36 | 77.00 | 130.25 | 0.5912 | -0.3071 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 106.00 | 130.25 | 0.8138 | 0.3201 | |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 123.00 | 130.25 | 0.9443 | 0.7819 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 156.25 | 92.36 | 100.00 | 130.25 | 0.7678 | 0.1737 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 105.00 | 130.25 | 0.8061 | 0.2951 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 156.25 | 92.36 | 68.00 | 130.25 | 0.5221 | -0.4607 |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 156.25 | 92.36 | 93.00 | 130.25 | 0.7140 | 0.0139 |
| SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 156.25 | 92.36 | 107.00 | 130.25 | 0.8215 | 0.3453 |